Invivyd (IVVD) Amortizatization of Intangibles (2021 - 2025)
Invivyd's (IVVD) quarterly Amortizatization of Intangibles came in at $286000.0 in Q4 2025, down 33.8% on a YoY basis from $432000.0 in Q4 2024, and up 1.42% quarter-over-quarter from $282000.0 in Q3 2025.
Analysis
Invivyd (IVVD) Amortizatization of Intangibles (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Amortizatization of Intangibles for 5 consecutive years, with $286000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Amortizatization of Intangibles fell 33.8% year-over-year to $286000.0; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (down 17.91% YoY), and the FY2025 full-year result was $1.4 million, down 17.91% from the prior year.
- Amortizatization of Intangibles advanced to $286000.0 in Q4 2025 per IVVD's latest filing, from $282000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.5 million in Q1 2023 and bottomed at -$4.7 million in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged $285555.6 across 5 years, with a median of $403500.0 in 2022.
- The widest YoY moves for Amortizatization of Intangibles: up 5358.06% in 2023, down 364.35% in 2023.
- Over 5 years, Amortizatization of Intangibles stood at -$2.0 million in 2021, then jumped by 188.74% to $1.8 million in 2022, then slumped by 364.35% to -$4.7 million in 2023, then soared by 109.18% to $432000.0 in 2024, then sank by 33.8% to $286000.0 in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $286000.0, $282000.0, and $352000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 678,000.00 |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 286,000.00 |
| Sep 30, 2025 | 282,000.00 |
| Jun 30, 2025 | 352,000.00 |
| Mar 31, 2025 | 432,000.00 |
| Dec 31, 2024 | 432,000.00 |
| Sep 30, 2024 | 427,000.00 |
| Jun 30, 2024 | 386,000.00 |
| Mar 31, 2024 | 402,000.00 |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | 1.69 Mn |
| Jun 30, 2023 | 2.02 Mn |
| Mar 31, 2023 | 2.54 Mn |
| Dec 31, 2022 | 1.78 Mn |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | 405,000.00 |
| Mar 31, 2022 | -194,000.00 |
| Dec 31, 2021 | -2.01 Mn |
| Sep 30, 2021 | 577,000.00 |